Hsp90 and Grp94 Inhibitors for the Treatment of Primary Open Angle Glaucoma
Promising diagnostic toolMay provide new opportunities for the treatment of additional diseases
therapeutic strategy for myocilin glaucoma
Our inventors have developed a novel strategy that holds considerable promise for treating myocilin glaucoma. Through selectively targeting the endoplasmic reticulum chaperone Grp94 using siRNA knockdown or small molecule inhibitors, mutant myocilin can be removed in an efficient manner. Additionally, analogous inhibition of the paralog Hsp90 is under investigation as a therapeutic approach for a variety of diseases including cancer and Alzheimer's disease. The potential benefits of this treatment offers a significant effort towards understanding and preventing this disease.
美國
